Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Что может стать альтернативой нестероидным противовоспалительным препаратам для контроля острой скелетно-мышечной боли у пациента, имевшего в анамнезе инфаркт миокарда и желудочно-кишечное кровотечение?
Что может стать альтернативой нестероидным противовоспалительным препаратам для контроля острой скелетно-мышечной боли у пациента, имевшего в анамнезе инфаркт миокарда и желудочно-кишечное кровотечение?
Каратеев А.Е. Что может стать альтернативой нестероидным противовоспалительным препаратам для контроля острой скелетно-мышечной боли у пациента, имевшего в анамнезе инфаркт миокарда и желудочно-кишечное кровотечение? Consilium Medicum. Неврология и Ревматология (Прил.). 2016; 1: 5–12.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Быстрое и максимально полное обезболивание является наиболее важной задачей при лечении пациентов с неспецифической болью в спине, остеоартрозом и ревматической патологией околосуставных мягких тканей. Современная концепция анальгетической терапии предполагает комплексный подход с использованием препаратов и методов лечения, влияющих на разные звенья патогенеза боли. Средством 1-й линии здесь выступают нестероидные противовоспалительные препараты (НПВП). Однако НПВП могут вызывать опасные осложнения, поэтому их использование существенно ограничено при серьезной коморбидной патологии желудочно-кишечного тракта и противопоказано при высоком кардиоваскулярном риске – например, у больных с клинически выраженной ишемической болезнью сердца, перенесенным инфарктом миокарда и инсультом. В настоящем обзоре рассматриваются анальгетики, которые могут стать более безопасной альтернативой НПВП в данной ситуации. Таким препаратом может считаться флупиртин, обезболивающий препарат с оригинальным механизмом действия, доказавший свою эффективность и безопасность в сравнении с НПВП и опиоидами в серии хорошо организованных клинических исследований.
Ключевые слова: скелетно-мышечная боль, анальгетическая терапия, нестероидные противовоспалительные препараты, осложнения, желудочно-кишечный тракт, кардиоваскулярный риск, парацетамол, трамадол, флупиртин.
Key words: musculoskeletal pain, analgesic therapy, non-steroidal anti-inflammatory drugs, complications, gastrointestinal tract, cardiovascular risk, paracetamol, tramadol, flupirtine.
Ключевые слова: скелетно-мышечная боль, анальгетическая терапия, нестероидные противовоспалительные препараты, осложнения, желудочно-кишечный тракт, кардиоваскулярный риск, парацетамол, трамадол, флупиртин.
________________________________________________
Key words: musculoskeletal pain, analgesic therapy, non-steroidal anti-inflammatory drugs, complications, gastrointestinal tract, cardiovascular risk, paracetamol, tramadol, flupirtine.
Полный текст
Список литературы
1. Боль (практическое руководство для врачей). Под ред. Н.Н.Яхно, М.Л.Кукушкина. М.: Издательство РАМН, 2012. / Bol' (prakticheskoe rukovodstvo dlia vrachei). Pod red. N.N.Iakhno, M.L.Kukushkina. M.: Izdatel'stvo RAMN, 2012 [in Russian]
2. Яхно Н.Н., Кукушкин М.Л. Хроническая боль: медико-биологические и социально-экономические аспекты. Вестн. РАМН. 2012; 9: 54–8. / Iakhno N.N., Kukush-kin M.L. Khronicheskaia bol': mediko-biologicheskie i sotsial'no-ekonomicheskie aspekty. Vestn. RAMN. 2012; 9: 54–8. [in Russian]
3. Насонов Е.Л., Насонова В.А. Фармакотерапия боли: взгляд ревматолога. Consilium Medicum. 2000; 2 (12): 7–14. / Nasonov E.L., Nasonova V.A. Farmakoterapiia boli: vzgliad revmatologa. Consilium Medicum. 2000; 2 (12): 7–14. [in Russian]
4. Blondell RD, Azadfard M, Wisniewski AM. Pharmacologic therapy for acute pain. Am Fam Physician 2013; 87 (11): 766–72.
5. Kroenke K, Krebs EE, Bair MJ. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry. 2009; 31 (3): 206–19. doi: 10.1016/j.genhosppsych. 2008.12.006. Epub 2009 Mar 4.
6. Каратеев А.Е., Насонов Е.Л., Яхно Н.Н. и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Соврем. ревматология. 2015; 1: 4–24. / Karateev A.E., Nasonov E.L., Iakhno N.N. i dr. Klinicheskie rekomendatsii “Ratsional'noe primenenie nesteroidnykh protivovospalitel'nykh preparatov (NPVP) v klinicheskoi praktike”. Sovrem. revmatologiia. 2015; 1: 4–24. [in Russian]
7. Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res 2015; 8: 105–18. doi: 10.2147/JPR.S75160. eCollection 2015.
8. McAlindon TE, Bannuru RR, Sullivan MC et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014; 22 (3): 363–88. doi: 10.1016/j.joca.2014.01.003. Epub 2014 Jan 24.
9. Bruyère O, Cooper C, Pelletier J-P et al. An algorithm recommendation for the management of knee Osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism 2014; 44: 253–63.
10. Koes BW, van Tulder M, Lin CW et al. An updated overview of clinical guidelines for the management of non-specific low back pain in primary care. Eur Spine J 2010; 19 (12): 2075–94.
11. Harirforoosh S, Asghar W, Jamali F. Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Pharm Sci 2013; 16 (5): 821–47.
12. Thomsen R, Riis A, Christensen S et al. Outcome of peptic ulcer bleeding among users of traditional non-steroidal anti-inflammatory drugs and selective cyclo-oxygenase-2 inhibitors. Aliment Pharmacol Ther 2006; 24 (10): 1431–8.
13. Thomsen R., Riis A., Munk E et al. 30-day mortality after peptic ulcer perforation among users of newer selective COX-2 inhibitors and traditional NSAIDs: a population-based study. Am J Gastroenterol 2006; 101 (12): 2704–10.
14. Del Piano M, Bianco MA, Cipolletta L et al. The "Prometeo" study: online collection of clinical data and outcome of Italian patients with acute nonvariceal upper gastrointestinal bleeding. J Clin Gastroenterol 2013; 47 (4): e33-7. doi: 10.1097/MCG.0b013e3182617dcc.
15. Silverstein F, Faich G, Goldstein J et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxid long-term arthritis safety study. JAMA 2000; 84: 1247–55.
16. Chan F, Wong V, Suen B et al. Combination of a cyclo-oxygenase-2 inhibitor and a pro-ton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007; 369: 1621–6.
17. Laine L, Curtis SP, Cryer B et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007; 369: 465–73.
18. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: 7086.
19. Gislason G, Jacobsen S, Rasmussen J et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflam-matory drugs after acute myocardial infarction. Circulation 2006; 113 (25): 2906–13.
20. Каратеев А.Е., Попкова Т.В., Новикова Д.С. и др. Оценка риска желудочно-кишечных и сердечно-сосудистых осложнений̆, ассоциированных с приемом нестероидных противовоспалительных препаратов в популяции СНГ. Научно-практическая ревматология. 2014; 52 (6): 600–6. / Karateev A.E., Popkova T.V., Novikova D.S. i dr. Otsenka riska zheludochno-kishechnykh i serdechno-sosudistykh oslozhneniĭ, assotsiirovannykh s priemom nesteroidnykh protivovospalitel'nykh preparatov v populiatsii SNG. Nauchno-prakticheskaia revmatologiia. 2014; 52 (6): 600– [in Russian]
21. Derry S, Moore R, Rabbie R. Topical NSAIDs for chronic muscoloskeletal pain in adults. Cochrane Database Sys Rev 2012; sep 12; 9 CD 007400.
22. Baraf H, Gloth F, Barthel H et al. Safety and efficacy of topical diclofenac sodium gel for knee osteoarthritis in elderly and younger patients: pooled data from three randomized, double-blind, parallel-group, placebo-controlled, multicentre trials. Drugs Aging 2011; 28 (1): 27–40.
23. Day R, Graham G, Whelton A. The position of paracetamol in the world of analgesics. Am J Therap 2000; 7: 51–5.
24. Prescott L. Paracetamol: past, present and future. Am J Therap 2000; 7: 135–43.
25. Machado G, Maher C, Ferreira P et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ 2015; 350: h1225. doi: 10.1136/bmj.h1225.
26. García Rodríguez L, Hernández-Díaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001; 12 (5): 570–6.
27. Chan A, Manson J, Albert C et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006; 113 (12): 1578–87.
28. Dedier J, Stampfer M, Hankinson S et al. Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension 2002; 40 (5): 604–8.
29. Forman J, Rimm E, Curhan G. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med 2007; 167 (4): 394–9.
30. Ong C, Seymour R, Lirk P, Merry A. Combining paracetamol (acetaminophen) with nonsteroidal antiinflammatory drugs: a qualitative systematic review of analgesic efficacy for acute postoperative pain. Anesth Analg 2010; 110 (4): 1170–9.
31. McQuay H, Edwards J. Meta-analysis of single dose oral tramadol plus acetaminophen in acute postoperative pain. Eur J Anaesthesiol (Suppl.) 2003; 28: 19–22.
32. Tiegs G, Karimi K, Brune K, Arck P. New problems arising from old drugs: second-generation effects of acetaminophen. Expert Rev Clin Pharmacol 2014; 7 (5): 655–62. doi: 10.1586/ 17512433.2014.944502. Epub 2014 Jul 30.
33. Bunchorntavakul C, Reddy KR. Acetaminophen-related hepatotoxicity. Clin Liver Dis 2013;17 (4): 587–607. viii. doi: 10.1016/j.cld.2013.07.005. Epub 2013 Sep 4.
34. Schaefert R, Welsch P, Klose P et al. Opioids in chronic osteoarthritis pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration. Schmerz 2015; 29 (1): 47–59. doi: 10.1007/s00482-014-1451-1.
35. Petzke F, Welsch P, Klose P et al. Opioids in chronic low back pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration. Schmerz 2015; 29 (1): 60–72. doi: 10.1007/s00482-014-1449-8.
36. Rosenberg M. The role of tramadol ER in the treatment of chronic pain. Int J Clin Pract 2009; 63 (10): 1531–43.
37. Peloso P, Fortin L, Beaulieu A et al. Analgesic efficacy and safety of tramadol/ acetaminophen combination tablets (Ultracet) in treatment of chronic low back pain: a multicenter, outpatient, randomized, double blind, placebo controlled trial. J Rheumatol 2004; 31 (12): 2454–63.
38. Perrot S, Krause D, Crozes P, Naïm C. Efficacy and tolerability of paracetamol/tramadol (325 mg/37.5 mg) combination treatment compared with tramadol (50 mg) monotherapy in patients with subacute low back pain: a multicenter, randomized, double-blind, parallel-group, 10-day treatment study. Clin Ther 2006; 28 (10): 1592–606.
39. Ананьева Л.П., Старовойтова М.Н., Десинова О.В. и др. Залдиар (трамадол/ацетаминофен) в лечении хронической боли при остеоартрозе. Consilium Medicum. 2007; 9 (12): 34–8. / Anan'eva L.P., Starovoitova M.N., Desinova O.V. i dr. Zaldiar (tramadol/atsetaminofen) v lechenii khronicheskoi boli pri osteoartroze. Consilium Medicum. 2007; 9 (12): 34–8. [in Russian]
40. Pavelka K, Pelisková Z, Stehlíková H et al. Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. Clin Drug Invest 1998;16 (6): 421–9.
41. Beaulieu A, Peloso P, Haraoui B et al. Once-daily, controlled-release tramadol and sus-tained-release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled tri-al. Pain Res Manag 2008; 13 (2): 103–10.
42. O'Donnell J, Ekman E, Spalding W et al. The effectiveness of a weak opioid medication versus a cyclo-oxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug in treating flare-up of chronic low-back pain: results from two randomized, double-blind, 6-week studies. J Int Med Res 2009; 37 (6): 1789–802.
43. Алексеева Л.И. Препараты замедленного действия в лечении остеоартроза. РМЖ. 2012; 7: 389–94.
44. Imagawa K, de Andrés M, Hashimoto K et al. The epigenetic effect of glucosamine and a nuclear factor-kappa B (NF-kB) inhibitor on primary human chondrocytes-implications for osteoarthritis. Biochem Biophys Res Commun 2011; 405 (3): 362–7.
45. Calamia V, Ruiz-Romero C, Rocha B et al. Pharmacoproteomic study of the effects of chondroitin and glucosamine sulfate on human articular chondrocytes. Arthritis Res Ther 2010; 12 (4): R138.
46. Au R, Au A, Rashmir-Raven A, Frondoza C. Inhibition pro-inflammatory gene expression in chondrocytes, monocytes, and fibroblasts by combination of avocado soybean unsaponiables, glucosamine and chondroitin sulfate. FASEB 2007; 21 (6): 702–7.
47. Towheed T, Maxwell L, Anastassiades T et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005; 2: CD002946.
48. Reichenbach S, Sterchi R, Scherer M et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 2007; 146 (8): 580–90.
49. Fidelix T, Soares B, Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev 2006; 1: CD005117.
50. Christensen R, Bartels E, Astrup A, Bliddal H. Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 2008; 16 (4): 399–408.
51. Singh G, Alekseeva L, Alexeev V, Triadafilopoulos G. Glucosamin-chondroitin sulfate reduces pain, disability and NSAID consumption in patients with chronic low back pain: a large, community-based, pilot, open prospective observational study. ELAR 2013; SAT0419.
52. Каратеев А.Е., Алексеева Л.И. Оценка переносимости диацереина в реальной клинической практике. Результаты исследования РОКАДА (ретроспективная оценка клинических аспектов применения диафлекса при остеоартрозе). Научно-практическая ревматология. 2015; 53 (2): 169–74. / Karateev A.E., Alekseeva L.I. Otsenka perenosimosti diatsereina v real'noi klinicheskoi praktike. Rezul'taty issledovaniia ROKADA (retrospektivnaia otsenka klinicheskikh aspektov primeneniia diafleksa pri osteoartroze). Nauchno-prakticheskaia revmatologiia. 2015; 53 (2): 169–74. [in Russian]
53. Bennell KL, Buchbinder R, Hinman RS. Physical therapies in the management of osteoarthritis: current state of the evidence. Curr Opin Rheumatol 2015; 27 (3): 304–11. doi: 10.1097/BOR.0000000000000160.
54. Rubinstein SM, Terwee CB, Assendelft WJ et al. Spinal manipulative therapy for acute low-back pain. Cochrane Database Syst Rev 2012; 9: CD008880. doi: 10.1002/14651858.CD008880.pub2.
55. Manheimer E, Cheng K, Linde K et al. Acupuncture for peripheral joint osteoarthritis. Cochrane Database Syst Rev 2010; 1: CD001977. doi: 10.1002/14651858.CD001977.pub2.
56. Raffa R, Pergolizzi Jr J. The evolving understanding of the analgesic mechanism of action of flupirtine. J Clin Pharm Ther 2012; 37: 4–6. doi: 10.1111/j.1365-2710.2010.01233.x
57. Devulder J. Flupirtine in Pain Management Pharmacological Properties and Clinical Use. CNS Drugs 2010; 24 (10): 867–81.
58. Klawe C, Maschke M. Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound. Exp Opin Pharmacother 2009; 10 (9): 1495–500.
59. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Flupirtine-containing_medicines/human_referral_prac_000019.jsp&mid=WC0b01ac05805c516f
60. Флупиртин. www.vidal.ru
61. Heusinger JH. Efficacy and tolerance of flupirtine and pentazocine in two multicentre trials. Postgrad Med J 1987; 63: 71–9.
62. Luben V, Muller H, Lobisch M, Wörz R. Treatment of tumor pain with flupirtine: Results of a double-blind study versus tramadol. Fortschr Med 1994; 112: 282–6.
63. Scheef W. Analgesic efficacy and safety of oral flupirtine in the treatment of cancer pain. Postgrad Med J 1987; 63: 67–70.
64. Mastronardi P, D’Onofrio M, Scanni E et al. Analgesic activity of flupirtine maleate: A controlled double-blind study with diclofenac sodium in orthopaedics. J Int Med Res 1988; 16: 338–48.
65. Riethmüller-Winzen H. Flupirtine in the treatment of post-operative pain. Postgrad Med J 1987; 63: 61–5.
66. Moore RA, Bullingham RE, Simpson S et al. Comparison of flupirtine maleate and dihydrocodeine in patients following surgery. Br J Anaesth 1983; 55: 429–32.
67. Worz R, Lobisch M, Schwittmann B et al. Effectiveness of flupirtine in chronic tension headache: results of a double- blind study versus placebo. Fortschr Med 1995; 113 (32): 463–8.
68. Mueller-Schwefe G. Flupirtine in acute and chronic pain associated with muscle tenseness: results of a postmarket surveillance study. Fortschr Med Orig 2003; 121 (1): 11–8.
69. Herrmann WM, Hiersemenzel R, Aigner M et al. Die Langzeitverträglichkeit von Flupirtin. Offene multizentrische Studie über ein Jahr. Fortschr Med 1993; 11: 46–50.
70. Uberall MA, Essner U, Müller-Schwefe GH. 2-week efficacy and tolerability of flupirtine MR and diclofenac in patients with acute low/back pain-results of a post-hoc subgroup analysis of patient-level data from four non-interventional studies. MMW Fortschr Med 2013; 155 (Suppl. 4): 115–23.
71. Marczyk LRS. Avaliacao comparativa do maleato de flupirtinaversus diclofenaco potassico em afeccoes musculoesqueleticas.Arq Bras Med 1992; 66 (3): 269–75.
72. Ueberall MA, Mueller-Schwefe GH, Terhaag B. Efficacy and tolerability of flupirtine in subacute/chronic musculoskeletal pain – results of a patient level, pooled re-analysis of randomized, double-blind, controlled trials. Int J Clin Pharmacol Ther 2011; 49 (11): 637–47.
73. Li C, Ni J, Wang Z et al. Analgesic efficacy and tolerability of flupirtine vs. tramadol in patients with subacute low back pain: a double-blind multicentre trial. Curr Med Res Opin 2008; 24 (12): 3523–30.
74. Uberall MA, Mueller-Schwefe GH, Terhaag B. Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallel-group phase IV study. Curr Med Res Opin 2012; 28 (10): 1617–34.
75. Левин Я.И., Стрыгин К.Н., Добровольская Л.Е. Катадолон в лечении боли в спине. Лечение нервных болезней. 2005; 6 (3): 12–17. / Levin Ia.I., Strygin K.N., Dobrovol'skaia L.E. Katadolon v lechenii boli v spine. Lechenie nervnykh boleznei. 2005; 6 (3): 12–17. [in Russian]
76. Камчатнов П.Р., Батышева Т.Т., Ганжула П.А. и др. Применение катадолона у больных со спондилогенной дорсалгией. Журн. неврологии и психиатрии. 2006; 106 (11): 46–8. / Kamchatnov P.R., Batysheva T.T., Ganzhula P.A. i dr. Primenenie katadolona u bol'nykh so spondilogennoĭ dorsalgieĭ. Zhurn. nevrologii i psikhiatrii. 2006; 106 (11): 46–8. [in Russian]
77. Данилов А.Б., Николаева Н.С. Эффективность новой формы флупиртина (Катадолона форте) в лечении острой̆ боли в спине. Managepain. 2013; 1: 44–8. / Danilov A.B., Nikolaeva N.S. Effektivnost' novoi formy flupirtina (Katadolona forte) v lechenii ostroĭ boli v spine. Managepain. 2013; 1: 44–8. [in Russian]
78. Эрдес Ш., Галушко Е., Зоткин Е. и др. Эффективность катадолона (флупиртина) у пациентов с болями в нижней̆ части спины. Врач. 2007; 5: 56–9. / Erdes Sh., Galushko E., Zotkin E. i dr. Effektivnost' katadolona (flupirtina) u patsientov s boliami v nizhneĭ chasti spiny. Vrach. 2007; 5: 56–9. [in Russian]
79. Michel MC, Radziszewski P, Falconer C et al. Unexpected frequent hepatotoxicity of a prescription drug, flupirtine, marketed for about 30 years. Br J Clin Pharmacol 2012; 73 (5): 821–5.
80. Douros A, Bronder E, Andersohn F et al. Flupirtine-induced liver injury-seven cases from the Berlin Case-control Surveillance Study and review of the German spontaneous adverse drug reaction reporting database. Eur J Clin Pharmacol 2014; 70 (4): 453–9. doi: 10.1007/s00228-013-1631-4. Epub 2013 Dec 24.
2. Iakhno N.N., Kukush-kin M.L. Khronicheskaia bol': mediko-biologicheskie i sotsial'no-ekonomicheskie aspekty. Vestn. RAMN. 2012; 9: 54–8. [in Russian]
3. Nasonov E.L., Nasonova V.A. Farmakoterapiia boli: vzgliad revmatologa. Consilium Medicum. 2000; 2 (12): 7–14. [in Russian]
4. Blondell RD, Azadfard M, Wisniewski AM. Pharmacologic therapy for acute pain. Am Fam Physician 2013; 87 (11): 766–72.
5. Kroenke K, Krebs EE, Bair MJ. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry. 2009; 31 (3): 206–19. doi: 10.1016/j.genhosppsych. 2008.12.006. Epub 2009 Mar 4.
6. Karateev A.E., Nasonov E.L., Iakhno N.N. i dr. Klinicheskie rekomendatsii “Ratsional'noe primenenie nesteroidnykh protivovospalitel'nykh preparatov (NPVP) v klinicheskoi praktike”. Sovrem. revmatologiia. 2015; 1: 4–24. [in Russian]
7. Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res 2015; 8: 105–18. doi: 10.2147/JPR.S75160. eCollection 2015.
8. McAlindon TE, Bannuru RR, Sullivan MC et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014; 22 (3): 363–88. doi: 10.1016/j.joca.2014.01.003. Epub 2014 Jan 24.
9. Bruyère O, Cooper C, Pelletier J-P et al. An algorithm recommendation for the management of knee Osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism 2014; 44: 253–63.
10. Koes BW, van Tulder M, Lin CW et al. An updated overview of clinical guidelines for the management of non-specific low back pain in primary care. Eur Spine J 2010; 19 (12): 2075–94.
11. Harirforoosh S, Asghar W, Jamali F. Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Pharm Sci 2013; 16 (5): 821–47.
12. Thomsen R, Riis A, Christensen S et al. Outcome of peptic ulcer bleeding among users of traditional non-steroidal anti-inflammatory drugs and selective cyclo-oxygenase-2 inhibitors. Aliment Pharmacol Ther 2006; 24 (10): 1431–8.
13. Thomsen R., Riis A., Munk E et al. 30-day mortality after peptic ulcer perforation among users of newer selective COX-2 inhibitors and traditional NSAIDs: a population-based study. Am J Gastroenterol 2006; 101 (12): 2704–10.
14. Del Piano M, Bianco MA, Cipolletta L et al. The "Prometeo" study: online collection of clinical data and outcome of Italian patients with acute nonvariceal upper gastrointestinal bleeding. J Clin Gastroenterol 2013; 47 (4): e33-7. doi: 10.1097/MCG.0b013e3182617dcc.
15. Silverstein F, Faich G, Goldstein J et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxid long-term arthritis safety study. JAMA 2000; 84: 1247–55.
16. Chan F, Wong V, Suen B et al. Combination of a cyclo-oxygenase-2 inhibitor and a pro-ton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007; 369: 1621–6.
17. Laine L, Curtis SP, Cryer B et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007; 369: 465–73.
18. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: 7086.
19. Gislason G, Jacobsen S, Rasmussen J et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflam-matory drugs after acute myocardial infarction. Circulation 2006; 113 (25): 2906–13.
20. Karateev A.E., Popkova T.V., Novikova D.S. i dr. Otsenka riska zheludochno-kishechnykh i serdechno-sosudistykh oslozhneniĭ, assotsiirovannykh s priemom nesteroidnykh protivovospalitel'nykh preparatov v populiatsii SNG. Nauchno-prakticheskaia revmatologiia. 2014; 52 (6): 600– [in Russian]
21. Derry S, Moore R, Rabbie R. Topical NSAIDs for chronic muscoloskeletal pain in adults. Cochrane Database Sys Rev 2012; sep 12; 9 CD 007400.
22. Baraf H, Gloth F, Barthel H et al. Safety and efficacy of topical diclofenac sodium gel for knee osteoarthritis in elderly and younger patients: pooled data from three randomized, double-blind, parallel-group, placebo-controlled, multicentre trials. Drugs Aging 2011; 28 (1): 27–40.
23. Day R, Graham G, Whelton A. The position of paracetamol in the world of analgesics. Am J Therap 2000; 7: 51–5.
24. Prescott L. Paracetamol: past, present and future. Am J Therap 2000; 7: 135–43.
25. Machado G, Maher C, Ferreira P et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ 2015; 350: h1225. doi: 10.1136/bmj.h1225.
26. García Rodríguez L, Hernández-Díaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001; 12 (5): 570–6.
27. Chan A, Manson J, Albert C et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006; 113 (12): 1578–87.
28. Dedier J, Stampfer M, Hankinson S et al. Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension 2002; 40 (5): 604–8.
29. Forman J, Rimm E, Curhan G. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med 2007; 167 (4): 394–9.
30. Ong C, Seymour R, Lirk P, Merry A. Combining paracetamol (acetaminophen) with nonsteroidal antiinflammatory drugs: a qualitative systematic review of analgesic efficacy for acute postoperative pain. Anesth Analg 2010; 110 (4): 1170–9.
31. McQuay H, Edwards J. Meta-analysis of single dose oral tramadol plus acetaminophen in acute postoperative pain. Eur J Anaesthesiol (Suppl.) 2003; 28: 19–22.
32. Tiegs G, Karimi K, Brune K, Arck P. New problems arising from old drugs: second-generation effects of acetaminophen. Expert Rev Clin Pharmacol 2014; 7 (5): 655–62. doi: 10.1586/ 17512433.2014.944502. Epub 2014 Jul 30.
33. Bunchorntavakul C, Reddy KR. Acetaminophen-related hepatotoxicity. Clin Liver Dis 2013;17 (4): 587–607. viii. doi: 10.1016/j.cld.2013.07.005. Epub 2013 Sep 4.
34. Schaefert R, Welsch P, Klose P et al. Opioids in chronic osteoarthritis pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration. Schmerz 2015; 29 (1): 47–59. doi: 10.1007/s00482-014-1451-1.
35. Petzke F, Welsch P, Klose P et al. Opioids in chronic low back pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration. Schmerz 2015; 29 (1): 60–72. doi: 10.1007/s00482-014-1449-8.
36. Rosenberg M. The role of tramadol ER in the treatment of chronic pain. Int J Clin Pract 2009; 63 (10): 1531–43.
37. Peloso P, Fortin L, Beaulieu A et al. Analgesic efficacy and safety of tramadol/ acetaminophen combination tablets (Ultracet) in treatment of chronic low back pain: a multicenter, outpatient, randomized, double blind, placebo controlled trial. J Rheumatol 2004; 31 (12): 2454–63.
38. Perrot S, Krause D, Crozes P, Naïm C. Efficacy and tolerability of paracetamol/tramadol (325 mg/37.5 mg) combination treatment compared with tramadol (50 mg) monotherapy in patients with subacute low back pain: a multicenter, randomized, double-blind, parallel-group, 10-day treatment study. Clin Ther 2006; 28 (10): 1592–606.
39. Anan'eva L.P., Starovoitova M.N., Desinova O.V. i dr. Zaldiar (tramadol/atsetaminofen) v lechenii khronicheskoi boli pri osteoartroze. Consilium Medicum. 2007; 9 (12): 34–8. [in Russian]
40. Pavelka K, Pelisková Z, Stehlíková H et al. Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. Clin Drug Invest 1998;16 (6): 421–9.
41. Beaulieu A, Peloso P, Haraoui B et al. Once-daily, controlled-release tramadol and sus-tained-release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled tri-al. Pain Res Manag 2008; 13 (2): 103–10.
42. O'Donnell J, Ekman E, Spalding W et al. The effectiveness of a weak opioid medication versus a cyclo-oxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug in treating flare-up of chronic low-back pain: results from two randomized, double-blind, 6-week studies. J Int Med Res 2009; 37 (6): 1789–802.
43. Алексеева Л.И. Препараты замедленного действия в лечении остеоартроза. РМЖ. 2012; 7: 389–94.
44. Imagawa K, de Andrés M, Hashimoto K et al. The epigenetic effect of glucosamine and a nuclear factor-kappa B (NF-kB) inhibitor on primary human chondrocytes-implications for osteoarthritis. Biochem Biophys Res Commun 2011; 405 (3): 362–7.
45. Calamia V, Ruiz-Romero C, Rocha B et al. Pharmacoproteomic study of the effects of chondroitin and glucosamine sulfate on human articular chondrocytes. Arthritis Res Ther 2010; 12 (4): R138.
46. Au R, Au A, Rashmir-Raven A, Frondoza C. Inhibition pro-inflammatory gene expression in chondrocytes, monocytes, and fibroblasts by combination of avocado soybean unsaponiables, glucosamine and chondroitin sulfate. FASEB 2007; 21 (6): 702–7.
47. Towheed T, Maxwell L, Anastassiades T et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005; 2: CD002946.
48. Reichenbach S, Sterchi R, Scherer M et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 2007; 146 (8): 580–90.
49. Fidelix T, Soares B, Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev 2006; 1: CD005117.
50. Christensen R, Bartels E, Astrup A, Bliddal H. Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 2008; 16 (4): 399–408.
51. Singh G, Alekseeva L, Alexeev V, Triadafilopoulos G. Glucosamin-chondroitin sulfate reduces pain, disability and NSAID consumption in patients with chronic low back pain: a large, community-based, pilot, open prospective observational study. ELAR 2013; SAT0419.
52. Karateev A.E., Alekseeva L.I. Otsenka perenosimosti diatsereina v real'noi klinicheskoi praktike. Rezul'taty issledovaniia ROKADA (retrospektivnaia otsenka klinicheskikh aspektov primeneniia diafleksa pri osteoartroze). Nauchno-prakticheskaia revmatologiia. 2015; 53 (2): 169–74. [in Russian]
53. Bennell KL, Buchbinder R, Hinman RS. Physical therapies in the management of osteoarthritis: current state of the evidence. Curr Opin Rheumatol 2015; 27 (3): 304–11. doi: 10.1097/BOR.0000000000000160.
54. Rubinstein SM, Terwee CB, Assendelft WJ et al. Spinal manipulative therapy for acute low-back pain. Cochrane Database Syst Rev 2012; 9: CD008880. doi: 10.1002/14651858.CD008880.pub2.
55. Manheimer E, Cheng K, Linde K et al. Acupuncture for peripheral joint osteoarthritis. Cochrane Database Syst Rev 2010; 1: CD001977. doi: 10.1002/14651858.CD001977.pub2.
56. Raffa R, Pergolizzi Jr J. The evolving understanding of the analgesic mechanism of action of flupirtine. J Clin Pharm Ther 2012; 37: 4–6. doi: 10.1111/j.1365-2710.2010.01233.x
57. Devulder J. Flupirtine in Pain Management Pharmacological Properties and Clinical Use. CNS Drugs 2010; 24 (10): 867–81.
58. Klawe C, Maschke M. Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound. Exp Opin Pharmacother 2009; 10 (9): 1495–500.
59. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Flupirtine-containing_medicines/human_referral_prac_000019.jsp&mid=WC0b01ac05805c516f
60. www.vidal.ru
61. Heusinger JH. Efficacy and tolerance of flupirtine and pentazocine in two multicentre trials. Postgrad Med J 1987; 63: 71–9.
62. Luben V, Muller H, Lobisch M, Wörz R. Treatment of tumor pain with flupirtine: Results of a double-blind study versus tramadol. Fortschr Med 1994; 112: 282–6.
63. Scheef W. Analgesic efficacy and safety of oral flupirtine in the treatment of cancer pain. Postgrad Med J 1987; 63: 67–70.
64. Mastronardi P, D’Onofrio M, Scanni E et al. Analgesic activity of flupirtine maleate: A controlled double-blind study with diclofenac sodium in orthopaedics. J Int Med Res 1988; 16: 338–48.
65. Riethmüller-Winzen H. Flupirtine in the treatment of post-operative pain. Postgrad Med J 1987; 63: 61–5.
66. Moore RA, Bullingham RE, Simpson S et al. Comparison of flupirtine maleate and dihydrocodeine in patients following surgery. Br J Anaesth 1983; 55: 429–32.
67. Worz R, Lobisch M, Schwittmann B et al. Effectiveness of flupirtine in chronic tension headache: results of a double- blind study versus placebo. Fortschr Med 1995; 113 (32): 463–8.
68. Mueller-Schwefe G. Flupirtine in acute and chronic pain associated with muscle tenseness: results of a postmarket surveillance study. Fortschr Med Orig 2003; 121 (1): 11–8.
69. Herrmann WM, Hiersemenzel R, Aigner M et al. Die Langzeitverträglichkeit von Flupirtin. Offene multizentrische Studie über ein Jahr. Fortschr Med 1993; 11: 46–50.
70. Uberall MA, Essner U, Müller-Schwefe GH. 2-week efficacy and tolerability of flupirtine MR and diclofenac in patients with acute low/back pain-results of a post-hoc subgroup analysis of patient-level data from four non-interventional studies. MMW Fortschr Med 2013; 155 (Suppl. 4): 115–23.
71. Marczyk LRS. Avaliacao comparativa do maleato de flupirtinaversus diclofenaco potassico em afeccoes musculoesqueleticas.Arq Bras Med 1992; 66 (3): 269–75.
72. Ueberall MA, Mueller-Schwefe GH, Terhaag B. Efficacy and tolerability of flupirtine in subacute/chronic musculoskeletal pain – results of a patient level, pooled re-analysis of randomized, double-blind, controlled trials. Int J Clin Pharmacol Ther 2011; 49 (11): 637–47.
73. Li C, Ni J, Wang Z et al. Analgesic efficacy and tolerability of flupirtine vs. tramadol in patients with subacute low back pain: a double-blind multicentre trial. Curr Med Res Opin 2008; 24 (12): 3523–30.
74. Uberall MA, Mueller-Schwefe GH, Terhaag B. Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallel-group phase IV study. Curr Med Res Opin 2012; 28 (10): 1617–34.
75. Levin Ia.I., Strygin K.N., Dobrovol'skaia L.E. Katadolon v lechenii boli v spine. Lechenie nervnykh boleznei. 2005; 6 (3): 12–17. [in Russian]
76. Kamchatnov P.R., Batysheva T.T., Ganzhula P.A. i dr. Primenenie katadolona u bol'nykh so spondilogennoĭ dorsalgieĭ. Zhurn. nevrologii i psikhiatrii. 2006; 106 (11): 46–8. [in Russian]
77. Danilov A.B., Nikolaeva N.S. Effektivnost' novoi formy flupirtina (Katadolona forte) v lechenii ostroĭ boli v spine. Managepain. 2013; 1: 44–8. [in Russian]
78. Erdes Sh., Galushko E., Zotkin E. i dr. Effektivnost' katadolona (flupirtina) u patsientov s boliami v nizhneĭ chasti spiny. Vrach. 2007; 5: 56–9. [in Russian]
79. Michel MC, Radziszewski P, Falconer C et al. Unexpected frequent hepatotoxicity of a prescription drug, flupirtine, marketed for about 30 years. Br J Clin Pharmacol 2012; 73 (5): 821–5.
80. Douros A, Bronder E, Andersohn F et al. Flupirtine-induced liver injury-seven cases from the Berlin Case-control Surveillance Study and review of the German spontaneous adverse drug reaction reporting database. Eur J Clin Pharmacol 2014; 70 (4): 453–9. doi: 10.1007/s00228-013-1631-4. Epub 2013 Dec 24.
2. Яхно Н.Н., Кукушкин М.Л. Хроническая боль: медико-биологические и социально-экономические аспекты. Вестн. РАМН. 2012; 9: 54–8. / Iakhno N.N., Kukush-kin M.L. Khronicheskaia bol': mediko-biologicheskie i sotsial'no-ekonomicheskie aspekty. Vestn. RAMN. 2012; 9: 54–8. [in Russian]
3. Насонов Е.Л., Насонова В.А. Фармакотерапия боли: взгляд ревматолога. Consilium Medicum. 2000; 2 (12): 7–14. / Nasonov E.L., Nasonova V.A. Farmakoterapiia boli: vzgliad revmatologa. Consilium Medicum. 2000; 2 (12): 7–14. [in Russian]
4. Blondell RD, Azadfard M, Wisniewski AM. Pharmacologic therapy for acute pain. Am Fam Physician 2013; 87 (11): 766–72.
5. Kroenke K, Krebs EE, Bair MJ. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry. 2009; 31 (3): 206–19. doi: 10.1016/j.genhosppsych. 2008.12.006. Epub 2009 Mar 4.
6. Каратеев А.Е., Насонов Е.Л., Яхно Н.Н. и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Соврем. ревматология. 2015; 1: 4–24. / Karateev A.E., Nasonov E.L., Iakhno N.N. i dr. Klinicheskie rekomendatsii “Ratsional'noe primenenie nesteroidnykh protivovospalitel'nykh preparatov (NPVP) v klinicheskoi praktike”. Sovrem. revmatologiia. 2015; 1: 4–24. [in Russian]
7. Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res 2015; 8: 105–18. doi: 10.2147/JPR.S75160. eCollection 2015.
8. McAlindon TE, Bannuru RR, Sullivan MC et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014; 22 (3): 363–88. doi: 10.1016/j.joca.2014.01.003. Epub 2014 Jan 24.
9. Bruyère O, Cooper C, Pelletier J-P et al. An algorithm recommendation for the management of knee Osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism 2014; 44: 253–63.
10. Koes BW, van Tulder M, Lin CW et al. An updated overview of clinical guidelines for the management of non-specific low back pain in primary care. Eur Spine J 2010; 19 (12): 2075–94.
11. Harirforoosh S, Asghar W, Jamali F. Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Pharm Sci 2013; 16 (5): 821–47.
12. Thomsen R, Riis A, Christensen S et al. Outcome of peptic ulcer bleeding among users of traditional non-steroidal anti-inflammatory drugs and selective cyclo-oxygenase-2 inhibitors. Aliment Pharmacol Ther 2006; 24 (10): 1431–8.
13. Thomsen R., Riis A., Munk E et al. 30-day mortality after peptic ulcer perforation among users of newer selective COX-2 inhibitors and traditional NSAIDs: a population-based study. Am J Gastroenterol 2006; 101 (12): 2704–10.
14. Del Piano M, Bianco MA, Cipolletta L et al. The "Prometeo" study: online collection of clinical data and outcome of Italian patients with acute nonvariceal upper gastrointestinal bleeding. J Clin Gastroenterol 2013; 47 (4): e33-7. doi: 10.1097/MCG.0b013e3182617dcc.
15. Silverstein F, Faich G, Goldstein J et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxid long-term arthritis safety study. JAMA 2000; 84: 1247–55.
16. Chan F, Wong V, Suen B et al. Combination of a cyclo-oxygenase-2 inhibitor and a pro-ton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007; 369: 1621–6.
17. Laine L, Curtis SP, Cryer B et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007; 369: 465–73.
18. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: 7086.
19. Gislason G, Jacobsen S, Rasmussen J et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflam-matory drugs after acute myocardial infarction. Circulation 2006; 113 (25): 2906–13.
20. Каратеев А.Е., Попкова Т.В., Новикова Д.С. и др. Оценка риска желудочно-кишечных и сердечно-сосудистых осложнений̆, ассоциированных с приемом нестероидных противовоспалительных препаратов в популяции СНГ. Научно-практическая ревматология. 2014; 52 (6): 600–6. / Karateev A.E., Popkova T.V., Novikova D.S. i dr. Otsenka riska zheludochno-kishechnykh i serdechno-sosudistykh oslozhneniĭ, assotsiirovannykh s priemom nesteroidnykh protivovospalitel'nykh preparatov v populiatsii SNG. Nauchno-prakticheskaia revmatologiia. 2014; 52 (6): 600– [in Russian]
21. Derry S, Moore R, Rabbie R. Topical NSAIDs for chronic muscoloskeletal pain in adults. Cochrane Database Sys Rev 2012; sep 12; 9 CD 007400.
22. Baraf H, Gloth F, Barthel H et al. Safety and efficacy of topical diclofenac sodium gel for knee osteoarthritis in elderly and younger patients: pooled data from three randomized, double-blind, parallel-group, placebo-controlled, multicentre trials. Drugs Aging 2011; 28 (1): 27–40.
23. Day R, Graham G, Whelton A. The position of paracetamol in the world of analgesics. Am J Therap 2000; 7: 51–5.
24. Prescott L. Paracetamol: past, present and future. Am J Therap 2000; 7: 135–43.
25. Machado G, Maher C, Ferreira P et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ 2015; 350: h1225. doi: 10.1136/bmj.h1225.
26. García Rodríguez L, Hernández-Díaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001; 12 (5): 570–6.
27. Chan A, Manson J, Albert C et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006; 113 (12): 1578–87.
28. Dedier J, Stampfer M, Hankinson S et al. Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension 2002; 40 (5): 604–8.
29. Forman J, Rimm E, Curhan G. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med 2007; 167 (4): 394–9.
30. Ong C, Seymour R, Lirk P, Merry A. Combining paracetamol (acetaminophen) with nonsteroidal antiinflammatory drugs: a qualitative systematic review of analgesic efficacy for acute postoperative pain. Anesth Analg 2010; 110 (4): 1170–9.
31. McQuay H, Edwards J. Meta-analysis of single dose oral tramadol plus acetaminophen in acute postoperative pain. Eur J Anaesthesiol (Suppl.) 2003; 28: 19–22.
32. Tiegs G, Karimi K, Brune K, Arck P. New problems arising from old drugs: second-generation effects of acetaminophen. Expert Rev Clin Pharmacol 2014; 7 (5): 655–62. doi: 10.1586/ 17512433.2014.944502. Epub 2014 Jul 30.
33. Bunchorntavakul C, Reddy KR. Acetaminophen-related hepatotoxicity. Clin Liver Dis 2013;17 (4): 587–607. viii. doi: 10.1016/j.cld.2013.07.005. Epub 2013 Sep 4.
34. Schaefert R, Welsch P, Klose P et al. Opioids in chronic osteoarthritis pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration. Schmerz 2015; 29 (1): 47–59. doi: 10.1007/s00482-014-1451-1.
35. Petzke F, Welsch P, Klose P et al. Opioids in chronic low back pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration. Schmerz 2015; 29 (1): 60–72. doi: 10.1007/s00482-014-1449-8.
36. Rosenberg M. The role of tramadol ER in the treatment of chronic pain. Int J Clin Pract 2009; 63 (10): 1531–43.
37. Peloso P, Fortin L, Beaulieu A et al. Analgesic efficacy and safety of tramadol/ acetaminophen combination tablets (Ultracet) in treatment of chronic low back pain: a multicenter, outpatient, randomized, double blind, placebo controlled trial. J Rheumatol 2004; 31 (12): 2454–63.
38. Perrot S, Krause D, Crozes P, Naïm C. Efficacy and tolerability of paracetamol/tramadol (325 mg/37.5 mg) combination treatment compared with tramadol (50 mg) monotherapy in patients with subacute low back pain: a multicenter, randomized, double-blind, parallel-group, 10-day treatment study. Clin Ther 2006; 28 (10): 1592–606.
39. Ананьева Л.П., Старовойтова М.Н., Десинова О.В. и др. Залдиар (трамадол/ацетаминофен) в лечении хронической боли при остеоартрозе. Consilium Medicum. 2007; 9 (12): 34–8. / Anan'eva L.P., Starovoitova M.N., Desinova O.V. i dr. Zaldiar (tramadol/atsetaminofen) v lechenii khronicheskoi boli pri osteoartroze. Consilium Medicum. 2007; 9 (12): 34–8. [in Russian]
40. Pavelka K, Pelisková Z, Stehlíková H et al. Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. Clin Drug Invest 1998;16 (6): 421–9.
41. Beaulieu A, Peloso P, Haraoui B et al. Once-daily, controlled-release tramadol and sus-tained-release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled tri-al. Pain Res Manag 2008; 13 (2): 103–10.
42. O'Donnell J, Ekman E, Spalding W et al. The effectiveness of a weak opioid medication versus a cyclo-oxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug in treating flare-up of chronic low-back pain: results from two randomized, double-blind, 6-week studies. J Int Med Res 2009; 37 (6): 1789–802.
43. Алексеева Л.И. Препараты замедленного действия в лечении остеоартроза. РМЖ. 2012; 7: 389–94.
44. Imagawa K, de Andrés M, Hashimoto K et al. The epigenetic effect of glucosamine and a nuclear factor-kappa B (NF-kB) inhibitor on primary human chondrocytes-implications for osteoarthritis. Biochem Biophys Res Commun 2011; 405 (3): 362–7.
45. Calamia V, Ruiz-Romero C, Rocha B et al. Pharmacoproteomic study of the effects of chondroitin and glucosamine sulfate on human articular chondrocytes. Arthritis Res Ther 2010; 12 (4): R138.
46. Au R, Au A, Rashmir-Raven A, Frondoza C. Inhibition pro-inflammatory gene expression in chondrocytes, monocytes, and fibroblasts by combination of avocado soybean unsaponiables, glucosamine and chondroitin sulfate. FASEB 2007; 21 (6): 702–7.
47. Towheed T, Maxwell L, Anastassiades T et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005; 2: CD002946.
48. Reichenbach S, Sterchi R, Scherer M et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 2007; 146 (8): 580–90.
49. Fidelix T, Soares B, Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev 2006; 1: CD005117.
50. Christensen R, Bartels E, Astrup A, Bliddal H. Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 2008; 16 (4): 399–408.
51. Singh G, Alekseeva L, Alexeev V, Triadafilopoulos G. Glucosamin-chondroitin sulfate reduces pain, disability and NSAID consumption in patients with chronic low back pain: a large, community-based, pilot, open prospective observational study. ELAR 2013; SAT0419.
52. Каратеев А.Е., Алексеева Л.И. Оценка переносимости диацереина в реальной клинической практике. Результаты исследования РОКАДА (ретроспективная оценка клинических аспектов применения диафлекса при остеоартрозе). Научно-практическая ревматология. 2015; 53 (2): 169–74. / Karateev A.E., Alekseeva L.I. Otsenka perenosimosti diatsereina v real'noi klinicheskoi praktike. Rezul'taty issledovaniia ROKADA (retrospektivnaia otsenka klinicheskikh aspektov primeneniia diafleksa pri osteoartroze). Nauchno-prakticheskaia revmatologiia. 2015; 53 (2): 169–74. [in Russian]
53. Bennell KL, Buchbinder R, Hinman RS. Physical therapies in the management of osteoarthritis: current state of the evidence. Curr Opin Rheumatol 2015; 27 (3): 304–11. doi: 10.1097/BOR.0000000000000160.
54. Rubinstein SM, Terwee CB, Assendelft WJ et al. Spinal manipulative therapy for acute low-back pain. Cochrane Database Syst Rev 2012; 9: CD008880. doi: 10.1002/14651858.CD008880.pub2.
55. Manheimer E, Cheng K, Linde K et al. Acupuncture for peripheral joint osteoarthritis. Cochrane Database Syst Rev 2010; 1: CD001977. doi: 10.1002/14651858.CD001977.pub2.
56. Raffa R, Pergolizzi Jr J. The evolving understanding of the analgesic mechanism of action of flupirtine. J Clin Pharm Ther 2012; 37: 4–6. doi: 10.1111/j.1365-2710.2010.01233.x
57. Devulder J. Flupirtine in Pain Management Pharmacological Properties and Clinical Use. CNS Drugs 2010; 24 (10): 867–81.
58. Klawe C, Maschke M. Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound. Exp Opin Pharmacother 2009; 10 (9): 1495–500.
59. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Flupirtine-containing_medicines/human_referral_prac_000019.jsp&mid=WC0b01ac05805c516f
60. Флупиртин. www.vidal.ru
61. Heusinger JH. Efficacy and tolerance of flupirtine and pentazocine in two multicentre trials. Postgrad Med J 1987; 63: 71–9.
62. Luben V, Muller H, Lobisch M, Wörz R. Treatment of tumor pain with flupirtine: Results of a double-blind study versus tramadol. Fortschr Med 1994; 112: 282–6.
63. Scheef W. Analgesic efficacy and safety of oral flupirtine in the treatment of cancer pain. Postgrad Med J 1987; 63: 67–70.
64. Mastronardi P, D’Onofrio M, Scanni E et al. Analgesic activity of flupirtine maleate: A controlled double-blind study with diclofenac sodium in orthopaedics. J Int Med Res 1988; 16: 338–48.
65. Riethmüller-Winzen H. Flupirtine in the treatment of post-operative pain. Postgrad Med J 1987; 63: 61–5.
66. Moore RA, Bullingham RE, Simpson S et al. Comparison of flupirtine maleate and dihydrocodeine in patients following surgery. Br J Anaesth 1983; 55: 429–32.
67. Worz R, Lobisch M, Schwittmann B et al. Effectiveness of flupirtine in chronic tension headache: results of a double- blind study versus placebo. Fortschr Med 1995; 113 (32): 463–8.
68. Mueller-Schwefe G. Flupirtine in acute and chronic pain associated with muscle tenseness: results of a postmarket surveillance study. Fortschr Med Orig 2003; 121 (1): 11–8.
69. Herrmann WM, Hiersemenzel R, Aigner M et al. Die Langzeitverträglichkeit von Flupirtin. Offene multizentrische Studie über ein Jahr. Fortschr Med 1993; 11: 46–50.
70. Uberall MA, Essner U, Müller-Schwefe GH. 2-week efficacy and tolerability of flupirtine MR and diclofenac in patients with acute low/back pain-results of a post-hoc subgroup analysis of patient-level data from four non-interventional studies. MMW Fortschr Med 2013; 155 (Suppl. 4): 115–23.
71. Marczyk LRS. Avaliacao comparativa do maleato de flupirtinaversus diclofenaco potassico em afeccoes musculoesqueleticas.Arq Bras Med 1992; 66 (3): 269–75.
72. Ueberall MA, Mueller-Schwefe GH, Terhaag B. Efficacy and tolerability of flupirtine in subacute/chronic musculoskeletal pain – results of a patient level, pooled re-analysis of randomized, double-blind, controlled trials. Int J Clin Pharmacol Ther 2011; 49 (11): 637–47.
73. Li C, Ni J, Wang Z et al. Analgesic efficacy and tolerability of flupirtine vs. tramadol in patients with subacute low back pain: a double-blind multicentre trial. Curr Med Res Opin 2008; 24 (12): 3523–30.
74. Uberall MA, Mueller-Schwefe GH, Terhaag B. Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallel-group phase IV study. Curr Med Res Opin 2012; 28 (10): 1617–34.
75. Левин Я.И., Стрыгин К.Н., Добровольская Л.Е. Катадолон в лечении боли в спине. Лечение нервных болезней. 2005; 6 (3): 12–17. / Levin Ia.I., Strygin K.N., Dobrovol'skaia L.E. Katadolon v lechenii boli v spine. Lechenie nervnykh boleznei. 2005; 6 (3): 12–17. [in Russian]
76. Камчатнов П.Р., Батышева Т.Т., Ганжула П.А. и др. Применение катадолона у больных со спондилогенной дорсалгией. Журн. неврологии и психиатрии. 2006; 106 (11): 46–8. / Kamchatnov P.R., Batysheva T.T., Ganzhula P.A. i dr. Primenenie katadolona u bol'nykh so spondilogennoĭ dorsalgieĭ. Zhurn. nevrologii i psikhiatrii. 2006; 106 (11): 46–8. [in Russian]
77. Данилов А.Б., Николаева Н.С. Эффективность новой формы флупиртина (Катадолона форте) в лечении острой̆ боли в спине. Managepain. 2013; 1: 44–8. / Danilov A.B., Nikolaeva N.S. Effektivnost' novoi formy flupirtina (Katadolona forte) v lechenii ostroĭ boli v spine. Managepain. 2013; 1: 44–8. [in Russian]
78. Эрдес Ш., Галушко Е., Зоткин Е. и др. Эффективность катадолона (флупиртина) у пациентов с болями в нижней̆ части спины. Врач. 2007; 5: 56–9. / Erdes Sh., Galushko E., Zotkin E. i dr. Effektivnost' katadolona (flupirtina) u patsientov s boliami v nizhneĭ chasti spiny. Vrach. 2007; 5: 56–9. [in Russian]
79. Michel MC, Radziszewski P, Falconer C et al. Unexpected frequent hepatotoxicity of a prescription drug, flupirtine, marketed for about 30 years. Br J Clin Pharmacol 2012; 73 (5): 821–5.
80. Douros A, Bronder E, Andersohn F et al. Flupirtine-induced liver injury-seven cases from the Berlin Case-control Surveillance Study and review of the German spontaneous adverse drug reaction reporting database. Eur J Clin Pharmacol 2014; 70 (4): 453–9. doi: 10.1007/s00228-013-1631-4. Epub 2013 Dec 24.
________________________________________________
2. Iakhno N.N., Kukush-kin M.L. Khronicheskaia bol': mediko-biologicheskie i sotsial'no-ekonomicheskie aspekty. Vestn. RAMN. 2012; 9: 54–8. [in Russian]
3. Nasonov E.L., Nasonova V.A. Farmakoterapiia boli: vzgliad revmatologa. Consilium Medicum. 2000; 2 (12): 7–14. [in Russian]
4. Blondell RD, Azadfard M, Wisniewski AM. Pharmacologic therapy for acute pain. Am Fam Physician 2013; 87 (11): 766–72.
5. Kroenke K, Krebs EE, Bair MJ. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry. 2009; 31 (3): 206–19. doi: 10.1016/j.genhosppsych. 2008.12.006. Epub 2009 Mar 4.
6. Karateev A.E., Nasonov E.L., Iakhno N.N. i dr. Klinicheskie rekomendatsii “Ratsional'noe primenenie nesteroidnykh protivovospalitel'nykh preparatov (NPVP) v klinicheskoi praktike”. Sovrem. revmatologiia. 2015; 1: 4–24. [in Russian]
7. Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res 2015; 8: 105–18. doi: 10.2147/JPR.S75160. eCollection 2015.
8. McAlindon TE, Bannuru RR, Sullivan MC et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014; 22 (3): 363–88. doi: 10.1016/j.joca.2014.01.003. Epub 2014 Jan 24.
9. Bruyère O, Cooper C, Pelletier J-P et al. An algorithm recommendation for the management of knee Osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism 2014; 44: 253–63.
10. Koes BW, van Tulder M, Lin CW et al. An updated overview of clinical guidelines for the management of non-specific low back pain in primary care. Eur Spine J 2010; 19 (12): 2075–94.
11. Harirforoosh S, Asghar W, Jamali F. Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Pharm Sci 2013; 16 (5): 821–47.
12. Thomsen R, Riis A, Christensen S et al. Outcome of peptic ulcer bleeding among users of traditional non-steroidal anti-inflammatory drugs and selective cyclo-oxygenase-2 inhibitors. Aliment Pharmacol Ther 2006; 24 (10): 1431–8.
13. Thomsen R., Riis A., Munk E et al. 30-day mortality after peptic ulcer perforation among users of newer selective COX-2 inhibitors and traditional NSAIDs: a population-based study. Am J Gastroenterol 2006; 101 (12): 2704–10.
14. Del Piano M, Bianco MA, Cipolletta L et al. The "Prometeo" study: online collection of clinical data and outcome of Italian patients with acute nonvariceal upper gastrointestinal bleeding. J Clin Gastroenterol 2013; 47 (4): e33-7. doi: 10.1097/MCG.0b013e3182617dcc.
15. Silverstein F, Faich G, Goldstein J et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxid long-term arthritis safety study. JAMA 2000; 84: 1247–55.
16. Chan F, Wong V, Suen B et al. Combination of a cyclo-oxygenase-2 inhibitor and a pro-ton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007; 369: 1621–6.
17. Laine L, Curtis SP, Cryer B et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007; 369: 465–73.
18. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: 7086.
19. Gislason G, Jacobsen S, Rasmussen J et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflam-matory drugs after acute myocardial infarction. Circulation 2006; 113 (25): 2906–13.
20. Karateev A.E., Popkova T.V., Novikova D.S. i dr. Otsenka riska zheludochno-kishechnykh i serdechno-sosudistykh oslozhneniĭ, assotsiirovannykh s priemom nesteroidnykh protivovospalitel'nykh preparatov v populiatsii SNG. Nauchno-prakticheskaia revmatologiia. 2014; 52 (6): 600– [in Russian]
21. Derry S, Moore R, Rabbie R. Topical NSAIDs for chronic muscoloskeletal pain in adults. Cochrane Database Sys Rev 2012; sep 12; 9 CD 007400.
22. Baraf H, Gloth F, Barthel H et al. Safety and efficacy of topical diclofenac sodium gel for knee osteoarthritis in elderly and younger patients: pooled data from three randomized, double-blind, parallel-group, placebo-controlled, multicentre trials. Drugs Aging 2011; 28 (1): 27–40.
23. Day R, Graham G, Whelton A. The position of paracetamol in the world of analgesics. Am J Therap 2000; 7: 51–5.
24. Prescott L. Paracetamol: past, present and future. Am J Therap 2000; 7: 135–43.
25. Machado G, Maher C, Ferreira P et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ 2015; 350: h1225. doi: 10.1136/bmj.h1225.
26. García Rodríguez L, Hernández-Díaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001; 12 (5): 570–6.
27. Chan A, Manson J, Albert C et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006; 113 (12): 1578–87.
28. Dedier J, Stampfer M, Hankinson S et al. Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension 2002; 40 (5): 604–8.
29. Forman J, Rimm E, Curhan G. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med 2007; 167 (4): 394–9.
30. Ong C, Seymour R, Lirk P, Merry A. Combining paracetamol (acetaminophen) with nonsteroidal antiinflammatory drugs: a qualitative systematic review of analgesic efficacy for acute postoperative pain. Anesth Analg 2010; 110 (4): 1170–9.
31. McQuay H, Edwards J. Meta-analysis of single dose oral tramadol plus acetaminophen in acute postoperative pain. Eur J Anaesthesiol (Suppl.) 2003; 28: 19–22.
32. Tiegs G, Karimi K, Brune K, Arck P. New problems arising from old drugs: second-generation effects of acetaminophen. Expert Rev Clin Pharmacol 2014; 7 (5): 655–62. doi: 10.1586/ 17512433.2014.944502. Epub 2014 Jul 30.
33. Bunchorntavakul C, Reddy KR. Acetaminophen-related hepatotoxicity. Clin Liver Dis 2013;17 (4): 587–607. viii. doi: 10.1016/j.cld.2013.07.005. Epub 2013 Sep 4.
34. Schaefert R, Welsch P, Klose P et al. Opioids in chronic osteoarthritis pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration. Schmerz 2015; 29 (1): 47–59. doi: 10.1007/s00482-014-1451-1.
35. Petzke F, Welsch P, Klose P et al. Opioids in chronic low back pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration. Schmerz 2015; 29 (1): 60–72. doi: 10.1007/s00482-014-1449-8.
36. Rosenberg M. The role of tramadol ER in the treatment of chronic pain. Int J Clin Pract 2009; 63 (10): 1531–43.
37. Peloso P, Fortin L, Beaulieu A et al. Analgesic efficacy and safety of tramadol/ acetaminophen combination tablets (Ultracet) in treatment of chronic low back pain: a multicenter, outpatient, randomized, double blind, placebo controlled trial. J Rheumatol 2004; 31 (12): 2454–63.
38. Perrot S, Krause D, Crozes P, Naïm C. Efficacy and tolerability of paracetamol/tramadol (325 mg/37.5 mg) combination treatment compared with tramadol (50 mg) monotherapy in patients with subacute low back pain: a multicenter, randomized, double-blind, parallel-group, 10-day treatment study. Clin Ther 2006; 28 (10): 1592–606.
39. Anan'eva L.P., Starovoitova M.N., Desinova O.V. i dr. Zaldiar (tramadol/atsetaminofen) v lechenii khronicheskoi boli pri osteoartroze. Consilium Medicum. 2007; 9 (12): 34–8. [in Russian]
40. Pavelka K, Pelisková Z, Stehlíková H et al. Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. Clin Drug Invest 1998;16 (6): 421–9.
41. Beaulieu A, Peloso P, Haraoui B et al. Once-daily, controlled-release tramadol and sus-tained-release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled tri-al. Pain Res Manag 2008; 13 (2): 103–10.
42. O'Donnell J, Ekman E, Spalding W et al. The effectiveness of a weak opioid medication versus a cyclo-oxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug in treating flare-up of chronic low-back pain: results from two randomized, double-blind, 6-week studies. J Int Med Res 2009; 37 (6): 1789–802.
43. Алексеева Л.И. Препараты замедленного действия в лечении остеоартроза. РМЖ. 2012; 7: 389–94.
44. Imagawa K, de Andrés M, Hashimoto K et al. The epigenetic effect of glucosamine and a nuclear factor-kappa B (NF-kB) inhibitor on primary human chondrocytes-implications for osteoarthritis. Biochem Biophys Res Commun 2011; 405 (3): 362–7.
45. Calamia V, Ruiz-Romero C, Rocha B et al. Pharmacoproteomic study of the effects of chondroitin and glucosamine sulfate on human articular chondrocytes. Arthritis Res Ther 2010; 12 (4): R138.
46. Au R, Au A, Rashmir-Raven A, Frondoza C. Inhibition pro-inflammatory gene expression in chondrocytes, monocytes, and fibroblasts by combination of avocado soybean unsaponiables, glucosamine and chondroitin sulfate. FASEB 2007; 21 (6): 702–7.
47. Towheed T, Maxwell L, Anastassiades T et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005; 2: CD002946.
48. Reichenbach S, Sterchi R, Scherer M et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 2007; 146 (8): 580–90.
49. Fidelix T, Soares B, Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev 2006; 1: CD005117.
50. Christensen R, Bartels E, Astrup A, Bliddal H. Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 2008; 16 (4): 399–408.
51. Singh G, Alekseeva L, Alexeev V, Triadafilopoulos G. Glucosamin-chondroitin sulfate reduces pain, disability and NSAID consumption in patients with chronic low back pain: a large, community-based, pilot, open prospective observational study. ELAR 2013; SAT0419.
52. Karateev A.E., Alekseeva L.I. Otsenka perenosimosti diatsereina v real'noi klinicheskoi praktike. Rezul'taty issledovaniia ROKADA (retrospektivnaia otsenka klinicheskikh aspektov primeneniia diafleksa pri osteoartroze). Nauchno-prakticheskaia revmatologiia. 2015; 53 (2): 169–74. [in Russian]
53. Bennell KL, Buchbinder R, Hinman RS. Physical therapies in the management of osteoarthritis: current state of the evidence. Curr Opin Rheumatol 2015; 27 (3): 304–11. doi: 10.1097/BOR.0000000000000160.
54. Rubinstein SM, Terwee CB, Assendelft WJ et al. Spinal manipulative therapy for acute low-back pain. Cochrane Database Syst Rev 2012; 9: CD008880. doi: 10.1002/14651858.CD008880.pub2.
55. Manheimer E, Cheng K, Linde K et al. Acupuncture for peripheral joint osteoarthritis. Cochrane Database Syst Rev 2010; 1: CD001977. doi: 10.1002/14651858.CD001977.pub2.
56. Raffa R, Pergolizzi Jr J. The evolving understanding of the analgesic mechanism of action of flupirtine. J Clin Pharm Ther 2012; 37: 4–6. doi: 10.1111/j.1365-2710.2010.01233.x
57. Devulder J. Flupirtine in Pain Management Pharmacological Properties and Clinical Use. CNS Drugs 2010; 24 (10): 867–81.
58. Klawe C, Maschke M. Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound. Exp Opin Pharmacother 2009; 10 (9): 1495–500.
59. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Flupirtine-containing_medicines/human_referral_prac_000019.jsp&mid=WC0b01ac05805c516f
60. www.vidal.ru
61. Heusinger JH. Efficacy and tolerance of flupirtine and pentazocine in two multicentre trials. Postgrad Med J 1987; 63: 71–9.
62. Luben V, Muller H, Lobisch M, Wörz R. Treatment of tumor pain with flupirtine: Results of a double-blind study versus tramadol. Fortschr Med 1994; 112: 282–6.
63. Scheef W. Analgesic efficacy and safety of oral flupirtine in the treatment of cancer pain. Postgrad Med J 1987; 63: 67–70.
64. Mastronardi P, D’Onofrio M, Scanni E et al. Analgesic activity of flupirtine maleate: A controlled double-blind study with diclofenac sodium in orthopaedics. J Int Med Res 1988; 16: 338–48.
65. Riethmüller-Winzen H. Flupirtine in the treatment of post-operative pain. Postgrad Med J 1987; 63: 61–5.
66. Moore RA, Bullingham RE, Simpson S et al. Comparison of flupirtine maleate and dihydrocodeine in patients following surgery. Br J Anaesth 1983; 55: 429–32.
67. Worz R, Lobisch M, Schwittmann B et al. Effectiveness of flupirtine in chronic tension headache: results of a double- blind study versus placebo. Fortschr Med 1995; 113 (32): 463–8.
68. Mueller-Schwefe G. Flupirtine in acute and chronic pain associated with muscle tenseness: results of a postmarket surveillance study. Fortschr Med Orig 2003; 121 (1): 11–8.
69. Herrmann WM, Hiersemenzel R, Aigner M et al. Die Langzeitverträglichkeit von Flupirtin. Offene multizentrische Studie über ein Jahr. Fortschr Med 1993; 11: 46–50.
70. Uberall MA, Essner U, Müller-Schwefe GH. 2-week efficacy and tolerability of flupirtine MR and diclofenac in patients with acute low/back pain-results of a post-hoc subgroup analysis of patient-level data from four non-interventional studies. MMW Fortschr Med 2013; 155 (Suppl. 4): 115–23.
71. Marczyk LRS. Avaliacao comparativa do maleato de flupirtinaversus diclofenaco potassico em afeccoes musculoesqueleticas.Arq Bras Med 1992; 66 (3): 269–75.
72. Ueberall MA, Mueller-Schwefe GH, Terhaag B. Efficacy and tolerability of flupirtine in subacute/chronic musculoskeletal pain – results of a patient level, pooled re-analysis of randomized, double-blind, controlled trials. Int J Clin Pharmacol Ther 2011; 49 (11): 637–47.
73. Li C, Ni J, Wang Z et al. Analgesic efficacy and tolerability of flupirtine vs. tramadol in patients with subacute low back pain: a double-blind multicentre trial. Curr Med Res Opin 2008; 24 (12): 3523–30.
74. Uberall MA, Mueller-Schwefe GH, Terhaag B. Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallel-group phase IV study. Curr Med Res Opin 2012; 28 (10): 1617–34.
75. Levin Ia.I., Strygin K.N., Dobrovol'skaia L.E. Katadolon v lechenii boli v spine. Lechenie nervnykh boleznei. 2005; 6 (3): 12–17. [in Russian]
76. Kamchatnov P.R., Batysheva T.T., Ganzhula P.A. i dr. Primenenie katadolona u bol'nykh so spondilogennoĭ dorsalgieĭ. Zhurn. nevrologii i psikhiatrii. 2006; 106 (11): 46–8. [in Russian]
77. Danilov A.B., Nikolaeva N.S. Effektivnost' novoi formy flupirtina (Katadolona forte) v lechenii ostroĭ boli v spine. Managepain. 2013; 1: 44–8. [in Russian]
78. Erdes Sh., Galushko E., Zotkin E. i dr. Effektivnost' katadolona (flupirtina) u patsientov s boliami v nizhneĭ chasti spiny. Vrach. 2007; 5: 56–9. [in Russian]
79. Michel MC, Radziszewski P, Falconer C et al. Unexpected frequent hepatotoxicity of a prescription drug, flupirtine, marketed for about 30 years. Br J Clin Pharmacol 2012; 73 (5): 821–5.
80. Douros A, Bronder E, Andersohn F et al. Flupirtine-induced liver injury-seven cases from the Berlin Case-control Surveillance Study and review of the German spontaneous adverse drug reaction reporting database. Eur J Clin Pharmacol 2014; 70 (4): 453–9. doi: 10.1007/s00228-013-1631-4. Epub 2013 Dec 24.
Авторы
А.Е.Каратеев*
ФГБНУ Научно-исследовательский институт ревматологии им. В.А.Насоновой. 115522, Россия, Москва, Каширское ш., д. 34А
*aekarateev@rambler.ru
V.A.Nasonova Research Institute of Rheumatology. 115522, Russian Federation, Moscow, Kashirskoe sh., d. 34A
*aekarateev@rambler.ru
ФГБНУ Научно-исследовательский институт ревматологии им. В.А.Насоновой. 115522, Россия, Москва, Каширское ш., д. 34А
*aekarateev@rambler.ru
________________________________________________
V.A.Nasonova Research Institute of Rheumatology. 115522, Russian Federation, Moscow, Kashirskoe sh., d. 34A
*aekarateev@rambler.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.